Biocon Ltd reports a sharp rise in first-quarter profit for financial year 2027, with net profit increasing to about ₹141 crore, up roughly three to four times year-on-year, depending on the outlet’s reported percentage. NDTV and other reports say revenue grows about 10% to above ₹4,300 crore (₹4,336 crore mentioned), while Business Line highlights growth led by Biocon’s biosimilars and generics businesses. Biosimilars revenue rises about 16% to ₹2,855 crore, and the generics business grows about 21% to ₹760 crore, according to the outlets that break down segment performance. Free Press Journal also notes consolidated total income increases to around ₹4,390.5 crore and total expenses rise as well. EBITDA margin is reported as stable by NDTV. The company attributes growth to its biopharma segment, including biosimilar and generic launches and expanded manufacturing capabilities, particularly in key international markets such as North America. Following the results, Biocon shares rise around 3% to 4% in reported trading after the announcement. Results also include an exceptional expense related to termination benefits, as cited by Free Press Journal.